Endotoxin and Cytokines Increase Hepatic Sphingolipid Biosynthesis and Produce Lipoproteins Enriched in Ceramides and Sphingomyelin

From the Departments of Medicine (R.A.M., A.H.M., J.F., J.K.S., C.G., K.R.F.) and Dermatology (W.M.H., T.S., Y.U.), University of California, San Francisco, and Metabolism Section, Medical and Dermatology Services, Veterans Affairs Medical Center, San Francisco, Calif.

Correspondence to Kenneth R. Feingold, MD, Metabolism Section (111F), Veterans Affairs Medical Center, 4150 Clement St, San Francisco, CA 94121. E-mail kfngld{at}itsa.ucsf.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Alterations in triglyceride and cholesterol metabolism often accompany inflammatory diseases and infections. We studied the effects of endotoxin (lipopolysaccharide [LPS]) and cytokines on hepatic sphingolipid synthesis, activity of serine palmitoyltransferase (SPT), the first and rate-limiting enzyme in sphingolipid synthesis, and lipoprotein sphingolipid content in Syrian hamsters. Administration of LPS induced a 2-fold increase in hepatic SPT activity. The increase in activity first occurred at 16 hours, peaked at 24 hours, and was sustained for at least 48 hours. Low doses of LPS produced maximal increases in SPT activity, with half-maximal effect seen at 0.3 µg LPS/100 g body weight. LPS increased hepatic SPT mRNA levels 2-fold, suggesting that the increase in SPT activity was due to an increase in SPT mRNA. LPS treatment also produced 75% and 2.5-fold increases in hepatic sphingomyelin and ceramide synthesis, respectively. Many of the metabolic effects of LPS are mediated by cytokines. Interleukin 1 (IL-1), but not tumor necrosis factor, increased both SPT activity and mRNA levels in the liver of intact animals, whereas both IL-1 and tumor necrosis factor increased SPT mRNA levels in HepG2 cells. IL-1 produced a 3-fold increase in SPT mRNA in HepG2 cells, and the half-maximal dose was 2 ng/mL. IL-1 also increased the secretion of sphingolipids into the medium. Analysis of serum lipoprotein fractions demonstrated that very low density lipoprotein, intermediate density lipoprotein, and low density lipoprotein isolated from animals treated with LPS contained significantly higher amounts of ceramide, glucosylceramide, and sphingomyelin. Taken together, these results indicate that LPS and cytokines stimulate hepatic sphingolipid synthesis, which results in an altered structure of circulating lipoproteins and may promote atherogenesis.

Key Words: acute-phase response • tumor necrosis factor • interleukin-1 • serine palmitoyltransferase • atherogenesis

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Alterations in triglyceride and cholesterol metabolism often accompany inflammatory diseases and infections.^{1 2} These metabolic alterations can also be induced by administration of endotoxin (lipopolysaccharide [LPS]), which mimics Gram-negative infections. Low doses of LPS rapidly increase serum triglyceride levels, primarily by stimulating hepatic triglyceride production and VLDL secretion.³ Increased hepatic fatty acid synthesis, as well as increased adipose tissue lipolysis, provides the fatty acid substrate for increased triglyceride production.³ High doses of LPS do not stimulate hepatic VLDL secretion³ but inhibit the clearance of triglyceride-rich lipoproteins by decreasing lipoprotein lipase activity in heart, muscle, and adipose tissue and in postheparin plasma.³

In rodents, LPS treatment increases serum cholesterol levels; however, this effect is delayed in onset compared with the increase in serum triglyceride levels and is primarily accounted for by an increase in LDL cholesterol.⁴ LPS increases hepatic cholesterol synthesis and the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis.⁴ Increased transcription of the HMG-CoA reductase gene leads to increased mRNA and protein levels, which account for the increase in hepatic HMG-CoA reductase activity.⁵ This effect of LPS on hepatic HMG-CoA reductase is specific, because mRNA levels of other important enzymes in cholesterol synthesis, such as HMG-CoA synthase, farnesyl pyrophosphate synthase, and squalene synthase, are not increased.^{5 6} In addition, LPS decreases the activity and mRNA levels of cholesterol 7-hydroxylase, the rate-limiting enzyme in bile acid synthesis.⁷ A decrease in bile acid synthesis would increase the availability of cholesterol for lipoprotein production. Finally, LPS has minimal or no effect on LDL receptor protein or mRNA levels in the liver, the organ primarily responsible for LDL clearance.⁴ These results suggest that the increased production of lipoproteins rather than a decrease in their clearance accounts for the increase in serum LDL cholesterol levels in rodents.

Sphingolipids not only are important constituents of cell membranes but also have a wide range of functions, including mediation of several signal transduction pathways that regulate cell growth, differentiation, and apoptosis.^{8 9 10} Recent studies have shown that the liver synthesizes sphingolipids de novo and incorporates these newly synthesized sphingolipids into VLDLs, which are secreted.¹¹ However, neither the addition of oleic acid, which accelerates hepatic VLDL secretion, nor choline deficiency, which inhibits hepatic VLDL secretion, alters the rate of hepatic sphingolipid synthesis,¹¹ suggesting that de novo sphingolipid synthesis is associated with, but not required for, VLDL secretion. Studies have shown that palmitate, but not other fatty acids, stimulates sphingolipid synthesis.¹² The relation between hepatic sphingolipid synthesis and the sphingolipid content of circulating lipoprotein particles has not been established.

The enzyme serine palmitoyltransferase (SPT) catalyzes the condensation of serine and palmitoyl CoA to form 3-ketosphinganine, the first and rate-limiting step in sphingolipid synthesis.¹³ A mammalian cDNA encoding the long-chain base 2 (LCB2) subunit of SPT was recently isolated.¹⁴ The factors that regulate sphingolipid synthesis and SPT activity in the liver have not been well characterized.

As described above, our previous studies have demonstrated that LPS and cytokines stimulate both hepatic fatty acid and cholesterol synthesis. Therefore, we hypothesized that LPS and cytokines may also stimulate hepatic sphingolipid synthesis. Hence, in this study, we examined the effects of LPS and cytokines on hepatic sphingolipid synthesis and SPT activity and mRNA levels in Syrian hamsters as well as in HepG2 cells. In addition, we measured the content of ceramides and sphingomyelin in lipoprotein fractions after LPS administration.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Materials
[-³²P]dCTP (3000 Ci/mmol) and [³H]serine (30 Ci/mmol) were purchased from New England Nuclear. LPS (Escherichia coli 55:B5) was purchased from Difco Laboratories and was freshly diluted to desired concentrations in pyrogen-free 0.9% saline (Kendall McGraw Laboratories, Inc). Human tumor necrosis factor (TNF)- with a specific activity of 5x10⁷ U/mg was provided by Genentech, Inc. Recombinant human interleukin (IL)-1ß with a specific activity of 1x10⁹ U/mg was provided by Immunex. The cytokines were freshly diluted to desired concentrations in pyrogen-free 0.9% saline containing 0.1% human serum albumin. High-performance thin-layer chromatography (HPTLC) plates (silica gel 60) were obtained from Merck. Chromatography standards, including ceramide, glucosylceramide, and sphingomyelin, were purchased from Sigma Chemical Co. A multiprime DNA-labeling system was purchased from Amersham International, minispin G-50 columns were from Worthington Biochemical Corp, oligo(dT) cellulose type 77F was from Pharmacia LKB Biotechnology AB, and Nytran membranes were from Schleicher & Schuell. Kodak XAR5 film was used for autoradiography. The cDNA for the LCB2 subunit of SPT¹⁴ was provided by Dr R. C. Dickson (University of Kentucky, Lexington).

Animal Procedures
Male Syrian hamsters (140 to 160 g) were purchased from Simonsen Laboratories (Gilroy, Calif). The animals were maintained in a reverse–light-cycle room (3 AM to 3 PM dark, 3 PM to 3 AM light) and were provided with rodent chow and water ad libitum. Anesthesia was induced with halothane, and the animals were injected intraperitoneally with either LPS, TNF, IL-1, or TNF plus IL-1 at the indicated doses in 0.5 mL of 0.9% saline or with saline alone. Food was subsequently withdrawn from both control and treated animals because LPS and cytokines may induce anorexia.² Animals were studied 4 to 48 hours after LPS administration or 16 hours after cytokine administration as indicated in the text. The doses of LPS used (0.1 to 100 µg/100 g bw) have significant effects on triglyceride and cholesterol metabolism in Syrian hamsters^{4 5 6 7} but are far below doses that cause death in rodents (LD₅₀ 5 mg/100 g bw). Similarly, the doses of TNF and IL-1 (17 and 1 µg/100 g bw, respectively) were chosen because previous studies have demonstrated that these doses have marked effects on serum lipid and lipoprotein levels and reproduce many of the effects of LPS on lipid metabolism in Syrian hamsters.^{6 7 15}

SPT Activity
At various time points after LPS treatment, livers were isolated and homogenized in 50 mmol/L HEPES, pH 7.4, containing 10 mmol/L EDTA, 5 mmol/L DTT, and 0.25 mol/L sucrose. Microsomes were isolated by differential centrifugation.¹⁶ Our assay for SPT activity was modified from the method of Williams et al¹³ as described earlier.¹⁶ In brief, the assay buffer contained 100 mmol/L HEPES, pH 8.3, 5.0 mmol/L DTT, and 2.5 mmol/L EDTA; the reaction mixture contained 50 µmol/L pyridoxal phosphate, 150 µmol/L palmitoyl-CoA, 1.0 mmol/L [³H]L-serine (specific activity, 45 to 50 000 dpm/nmol), and 50 to 100 µg of microsomal protein in 0.1 mL of total assay volume. The assay mixture (protein, buffer, and pyridoxal phosphate) was preincubated for 10 minutes (37°C), and the assay was initiated by simultaneous addition of palmitoyl-CoA and [³H]L-serine, incubated at 37°C for 10 minutes, and terminated by the addition of 0.2 mL of 0.5N NH₄OH. The reaction product, 3-ketodihydrosphinganine, was isolated as described previously and counted by liquid scintillation spectrometry. Enzyme specific activity was expressed as picomoles of 3-ketodihydrosphinganine formed per minute per milligram of microsomal protein. Protein was determined by the Bradford procedure using BSA as the standard.

Isolation of RNA and Northern Blotting
Total RNA was isolated by a variation of the guanidinium thiocyanate method¹⁷ as described earlier.⁴ Poly A⁺ RNA from liver was isolated using oligo(dT) cellulose. Poly A⁺ RNA was quantified by measuring absorption at 260 nm. Equal amounts of poly A⁺ RNA were loaded on 1% agarose-formaldehyde gels and electrophoresed. The uniformity of sample applications was checked by UV visualization of the acridine orange–stained gels before transfer to Nytran membranes. We and others have found that LPS increases actin mRNA levels in liver by 2-fold to 5-fold in rodents.^{4 18} TNF and IL-1 produce a 2-fold increase in actin mRNA levels. LPS also produced a 2-fold increase in hepatic mRNA levels for glyceraldehyde 3-phosphate dehydrogenase (G-3PD) and a 2.6-fold increase in cyclophilin mRNA.¹⁹ Thus, the mRNA levels of actin, G-3PD, and cyclophilin, which are widely used for normalizing data, cannot be used to study LPS-induced or cytokine-induced regulation of proteins in liver. However, the differing direction of the changes in mRNA levels for specific proteins after LPS or cytokine administration, the magnitude of the alterations, and the relatively small standard error of the mean make it unlikely that the changes observed were due to unequal loading of mRNA.^{4 5 6 7 19} cDNA probe hybridization was performed in 0.75 mol/L NaCl, 0.075 mol/L sodium citrate, 2% SDS, 10% dextran sulfate, 2x Denhardt's solution, and 100 mg/mL sheared salmon sperm DNA at 65°C overnight. The blots were washed in 0.2x SSC and 0.1% SDS at room temperature for 30 minutes and at 65°C for 1 hour. The blots were exposed to x-ray films for various durations to ensure that measurements were done on the linear portion of the curve, and the bands were quantified by densitometry.

Sphingolipid Synthesis
Twenty-four hours after LPS administration, the animals were killed and the liver removed. Slices (0.5 mm thick) were prepared with a McIlwain tissue slicer, and 200 mg of tissue was placed in the outer well of a 25-mL flask containing 2 mL of Krebs-Ringer phosphate buffer and [³H]serine (1 mCi, Dupont-NEN). The flasks were gassed with 95% O₂/5% CO₂ for 15 seconds, stoppered with serum caps, and incubated for 1 hour at 37°C in a Dubnoff metabolic shaker at 100 oscillations/min. At the end of the incubation, Bligh-Dyer solution was added and total lipid extracts obtained.²⁰ The lipid components were separated by HPTLC as described earlier¹⁶ using the following solvent sequence: (1) chloroform:methanol:water 90:10:1 (by volume), (2) petroleum ether:diethylether:acetic acid 70:50:1 (by volume), and (3) chloroform:methanol:water:acetic acid 60:35:4.5:0.5 (by volume) to 15 cm. Lipids were visualized by Woods light fluorescence after staining with 8-anilino-1-naphthalene sulfonic acid and identified by cochromatography against known standards. The lipid spots corresponding to ceramides and sphingomyelin were scraped into scintillation vials and counted by liquid scintillation spectrometry.

HepG2 Cell Culture and Cytokine Treatment
HepG2 cells were obtained from the American Type Culture Collection (Rockville, Md) and maintained in minimum essential medium (Mediatech, Inc) supplemented with 10% FBS under standard culture conditions (5% CO₂, 37°C). Cells were seeded into 100-mm culture dishes and allowed to grow to 80% confluence. Immediately before the experiment, cells were washed with calcium-free and magnesium-free PBS, and the experimental medium (Dulbecco's minimum essential medium plus 0.1% BSA) containing TNF or IL-1 at the indicated concentrations was added. Cells were incubated at 37°C for the indicated time. RNA purification and Northern blotting were performed according to previously described methods.^{4 7}

Isolation of Lipoproteins
Twenty-four hours after LPS treatment, blood was collected in tubes containing EDTA (1.5 mg/mL) and plasma was isolated. Lipoprotein fractions were isolated using the fast protein liquid chromatography system (Pharmacia Biotech, Inc) equipped with 2 Superose 6 HR 10/30 columns connected in series.²¹ In brief, plasma was centrifuged at 12 000g, and a 0.5-mL aliquot of clear supernatant was loaded. Lipoproteins were eluted at a flow rate of 0.5 mL/min with a buffer (pH 7.4) containing 10 mmol/L NaH₂PO₄, 150 mmol/L NaCl, 1 mmol/L EDTA, and 0.02% (wt/vol) NaN₃. After the initial 12 mL was eluted, 50 fractions of 0.5 mL were collected. A total of 80 mL was passed through the columns before the next sample was loaded. Cholesterol and triglyceride concentrations in the fractions were measured by commercially available enzyme assay kits to identify the peaks of lipoprotein fractions. VLDL, IDL, LDL, and HDL fractions were pooled for isolation of ceramides and sphingomyelin in each fraction.

Analysis of Ceramides and Sphingomyelin in Lipoproteins
Total lipids were extracted from pooled lipoprotein fractions by the Bligh-Dyer technique²⁰ and dried. The dried lipid extracts were redissolved in chloroform:methanol (4:1), and an aliquot of each sample was dried in an aluminum dish on a heater (60°C) and weighed. Approximately 50 µg of lipid from each sample was applied to HPTLC plates, along with standards to separate ceramide, glucosylceramide, and sphingomyelin. Ceramide and glucosylceramide were separated using the following solvent sequence: (1) chloroform:methanol:acetone (70:20:4 by volume) to 2 cm (from the applied position), (2) chloroform:methanol:acetone (80:10:10 by volume) to 6 cm, and (3) chloroform:diethylether:ethyl acetate:methanol (76:6:20:4 by volume) to the top of the plate. Sphingomyelin was separated by using chloroform:methanol:acetic acid:water (50:30:8:4 by volume) twice to the top. After development, the plates were dried (60°C), sprayed with a charring solution (containing 1.5% copper sulfate, 5% glacial acetic acid, 1% sulfuric acid, and 1% ortho-phospholic acid), and charred in an oven (180°C) for 15 minutes. The charred plates were scanned with a TLC scanner (CAMAG Scientific, Inc), and the bands were quantified against the standards as previously described.²²

Statistics
Results are expressed as mean±SEM. Statistical significance between 2 groups was determined by using the Student t test. Comparisons among several groups were done by ANOVA. When SDs were unequal, a nonparametric test (Mann-Whitney) was used to calculate the level of significance.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Endotoxin Increases Hepatic SPT Activity and mRNA Levels
Our initial experiments determined the effect of LPS administration on SPT activity in the liver of Syrian hamsters. As shown in Figure 1A, SPT activity increases 2-fold 16 hours after LPS treatment. The increase in SPT activity after LPS administration peaks at 24 hours (3-fold increase) and is sustained for at least 48 hours. We next determined the dose-response curve for the effect of LPS on hepatic SPT activity 16 hours after LPS administration (Figure 1B). Relatively low doses of LPS cause a maximal increase in SPT activity (1 µg/100 g bw), and the half-maximal effect is seen with 0.3 µg/100 g bw, indicating that the increase in SPT activity is a very sensitive host response to LPS.

View larger version (13K): [in this window] [in a new window]   Figure 1. Time course (A) and dose response (B) for effect of LPS on SPT activity in liver. Syrian hamsters were injected intraperitoneally with either saline or LPS (100 µg/100 g bw) (A) or with LPS at doses indicated on the x axis (B). Animals were killed at various time points (A) or 16 hours after LPS administration (B), liver microsomes were isolated, and SPT activity was determined as described in Methods. SPT activity in the control group was 23.64±1.33 pmol · min-1 · mg-1 protein. Data are mean±SEM; n=5 for each group. A, *P<0.001. B, *P<0.05, **P<0.002, and ***P<0.001. CON indicates control.

To determine the potential mechanism by which LPS increases SPT activity, we determined the effect of 16-hour LPS treatment on hepatic SPT mRNA levels in Syrian hamsters. LPS treatment produced a 2-fold increase in mRNA levels of the LCB2 subunit of SPT in liver (Figure 2). These data suggest that the increase in hepatic SPT activity is due to an increase in SPT mRNA levels.

View larger version (34K): [in this window] [in a new window]   Figure 2. Effect of LPS on hepatic SPT mRNA. Animals were injected intraperitoneally with either saline or LPS (100 µg/100 g bw). Sixteen hours later, the animals were killed, livers were obtained, and poly A+ RNA was isolated. Northern blots were probed with SPT cDNA as described in Methods. Data are presented as the percentage of control values as quantified by densitometry (mean±SEM); n=5 for the control group and 4 for the LPS group. *P<0.05.

Endotoxin Increases Incorporation of [³H]Serine in Hepatic Sphingolipids
We next examined whether LPS administration also increases hepatic sphingolipid synthesis as measured by the incorporation of [³H]serine into hepatic ceramides and sphingomyelin. Syrian hamsters were treated with LPS (100 µg/100 g bw), and 24 hours later the incorporation of [³H]serine into sphingolipids was measured in liver slices. LPS produced a 2.5-fold increase in [³H]serine incorporation into hepatic ceramides and a 75% increase in incorporation into hepatic sphingomyelin (Figure 3). Thus, the increases in hepatic SPT activity and mRNA levels induced by LPS are reflected in increased sphingolipid synthesis in liver.

View larger version (36K): [in this window] [in a new window]   Figure 3. Effect of LPS on hepatic sphingolipid synthesis. Animals were injected intraperitoneally with either saline or LPS (100 µg/100 g bw). Twenty-four hours later, the animals were killed, liver slices were prepared, and the incorporation of [3H]serine into ceramides and sphingomyelin was measured as described in Methods. Data are mean±SEM; n=5 for each group. *P<0.1 and **P<0.02. CON indicates control.

IL-1 Increases Hepatic SPT Activity and mRNA Levels
Many of the metabolic effects of LPS are mediated by cytokines² ; therefore, we next examined the effect of TNF, IL-1, and the combination of TNF and IL-1 on hepatic SPT activity and mRNA levels in Syrian hamsters. As shown in Figure 4A, administration of IL-1 produces a 50% increase in SPT activity (compared with saline-treated controls), whereas the combination of TNF and IL-1 results in an 80% increase in SPT activity. In contrast, TNF alone did not alter hepatic SPT activity. With regard to hepatic SPT mRNA levels, IL-1 produced a 3.3-fold increase, whereas treatment with IL-1 plus TNF produced a 2.6-fold increase in SPT mRNA levels (Figure 4B). TNF alone had no effect on SPT mRNA levels. Although the magnitude of the IL-1–induced increases in SPT activity and mRNA shows a trend toward being different from that seen with the combination of TNF and IL-1, these differences are not statistically significant. These results indicate that IL-1 regulates SPT at the level of both activity and mRNA, whereas TNF has no effect in hamsters in vivo.

View larger version (34K): [in this window] [in a new window]   Figure 4. Effect of cytokines on hepatic SPT activity (A) and mRNA (B) levels. Animals were injected intraperitoneally with saline, TNF, or IL-1 at doses indicated in the text. Sixteen hours later, the animals were killed and livers were obtained for isolation of microsomes and RNA. SPT activity (A) and mRNA levels (B) were measured as described in Methods. SPT activity in the control group was 19.4±0.72 pmol · min-1 mg-1 protein. Data are mean±SEM; n=5 for all groups. A, *P<0.005. B, *P<0.02 and **P<0.002. T + I indicates TNF and IL-1; CON, control.

IL-1 Increases SPT mRNA Levels and Sphingolipid Secretion in Cultured HepG2 Cells
To determine whether cytokines directly affect hepatocyte SPT mRNA levels, we next examined the effect of TNF and IL-1 in HepG2 cells, a human hepatoma cell line. As shown in Figure 5, TNF and IL-1 increase SPT mRNA levels in HepG2 cells by 2-fold and 3-fold, respectively. IL-6, another cytokine known to affect lipid metabolism,² also produced a 2.7-fold increase in SPT mRNA in HepG2 cells (data not shown). Because IL-1 had a greater effect than TNF and also induced changes in vivo, we examined the effect of IL-1 on HepG2 SPT mRNA levels in more detail. As shown in Figure 6A, IL-1 significantly increased SPT mRNA levels after 8 hours of treatment, and this increase was sustained for at least 48 hours. The dose response of 48-hour treatment with IL-1 on SPT mRNA in HepG2 cells is shown in Figure 6B. The data show that low doses of IL-1 increase SPT mRNA levels in HepG2 cells. The maximal effect was seen at 10 to 100 ng/mL, whereas the half-maximal effect was observed at 2 ng/mL.

View larger version (44K): [in this window] [in a new window]   Figure 5. Effect of cytokines on SPT mRNA in HepG2 cells. TNF or IL-1 was added to HepG2 cells at a concentration of 100 ng/mL. Twenty-four hours later, poly A+ RNA was isolated and Northern blots were probed with SPT cDNA as described in Methods. Data are presented as the percentage of control values as quantified by densitometry (mean±SEM); n=4 for control and TNF groups and 3 for the IL-1 group. A, *P<0.01 and **P<0.001. CON indicates control.

View larger version (13K): [in this window] [in a new window]   Figure 6. Time course (A) and dose response (B) for the effect of IL-1 on SPT mRNA in HepG2 cells. HepG2 cells were incubated with the indicated doses of IL-1 for various time points (A) or for 48 hours (B). At the end of the incubations, poly A+ RNA was isolated and Northern blots were probed with SPT cDNA as described in Methods. Data are mean±SEM; n=4 for all groups. A, *P<0.05, **P<0.02, and ***P<0.01. B, *P<0.05, **P<0.01, and ***P<0.001. CON indicates control.

We next determined the effect of IL-1 on the secretion of newly synthesized sphingolipids from HepG2 cells into the medium. The data in Figure 7 show that IL-1 significantly increased the secretion of labeled sphingolipids into the medium in a time-dependent manner (40% and 3.8-fold increases at 4 and 8 hours, respectively). Thus, IL-1 is capable of regulating SPT mRNA levels as well as sphingolipid secretion in HepG2 cells.

View larger version (13K): [in this window] [in a new window]   Figure 7. Effect of IL-1 on secretion of sphingolipids into the medium. HepG2 cells were incubated with 100 ng/mL IL-1 and 20 µCi/mL [3H]serine for the indicated times. At the end of incubation, the medium was removed from the cells and centrifuged to remove any cells. The medium was extracted and analyzed for total sphingolipid secretion as described in Methods. Data are mean±SEM; n=4 for all groups. *P<0.005 and **P<0.001. CON indicates control.

LPS Increases the Content of Ceramides and Sphingomyelin in Lipoprotein Fractions
Our previous studies have shown that LPS increases serum cholesterol and triglyceride levels in Syrian hamsters and alters the composition of lipoproteins, resulting in triglyceride-rich and cholesterol-rich particles.⁴ In this study, we isolated the lipoproteins by FPLC and measured the content of cholesterol and triglycerides in each FPLC fraction to characterize the peaks for different lipoprotein fractions. Both cholesterol and triglyceride content of the VLDL, IDL, LDL, and HDL fractions were increased in plasma samples from LPS-treated animals (data not shown).

FPLC fractions were pooled, on the basis of peaks for VLDL, IDL, LDL, and HDL, for LPS-treated and control samples, and total lipids were extracted.¹⁷ LPS significantly increased the amount of total extractable lipid (in mg/mL plasma) in the VLDL (control 2.09±0.18, LPS 3.5±0.31, P<0.003), IDL (control 0.85±0.04, LPS 1.5±0.08, P<0.001), and LDL (control 1.14±0.05, LPS 2.54±0.12, P<0.001) fractions. However, the effect of LPS on total extractable lipid in the HDL fraction was not significant (control 2.92±0.08, LPS 3.33±0.16).

The data in Figure 8 demonstrate the effect of 24-hour LPS treatment on the levels of ceramide, glucosylceramide, and sphingomyelin in different lipoprotein fractions. Because LPS also increased total extractable lipid in different lipoprotein fractions, we analyzed the data on ceramide, glucosylceramide, and sphingomyelin content in various lipoprotein fractions per milligram of total lipid to account for the LPS-induced increase in total lipid content. Consistent with previous findings,¹¹ ceramide and glucosylceramide levels were low in all lipoprotein fractions from control animals (Figure 8A and 8B). LPS treatment significantly increased the levels of ceramide (Figure 8A) and glucosylceramide (Figure 8B) in each lipoprotein fraction. The most marked increase was seen in the VLDL fraction (3.7-fold and 18.9-fold increases in ceramide and glucosylceramide content, respectively). There was also a 2.2-fold increase in ceramide content and a 7.3-fold increase in glucosylceramide content in the LDL fraction from LPS-treated animals. The basal level of sphingomyelin was higher than the basal levels of ceramide and glucosylceramide in the VLDL, LDL, and HDL fractions (Figure 8C). LPS significantly increased sphingomyelin content in the IDL and LDL fractions (Figure 8C) but had no effect on sphingomyelin content in the VLDL and HDL fractions.

View larger version (19K): [in this window] [in a new window]   Figure 8. Effect of LPS on ceramide (A), glucosylceramide (B), and sphingomyelin (C) content (µg/mg total lipid) in lipoprotein fractions. Syrian hamsters were injected with saline or LPS (100 µg/100 g bw), and blood was collected 24 hours later. Plasma was obtained, and lipoprotein fractions were isolated by FPLC. The fractions for VLDL, IDL, LDL, and HDL were pooled, and total lipids were extracted. Individual sphingolipids were isolated by HPTLC and quantified as described in Methods. Data are mean±SEM; n=6 for all groups. A, *P<0.02 and **P<0.008. B, *P<0.01 and **P<0.002. C, *P<0.002. CON indicates control.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Sphingolipids are important components of the plasma membranes of all eukaryotic cells and have a wide range of functions. However, relatively little is known about the factors that regulate de novo sphingolipid synthesis or the activity of SPT, the first and rate-limiting enzyme in sphingolipid biosynthesis. In this study, we demonstrated that LPS stimulates hepatic sphingomyelin and ceramide synthesis in vivo. In addition, LPS produces a marked increase in SPT activity in the liver. This increase in SPT activity occurs at very low doses of LPS (1 µg/100 g bw) and is first observed 16 hours after LPS treatment. Moreover, these changes in SPT activity are accompanied by an increase in SPT mRNA levels in the liver. These results indicate that LPS increases hepatic sphingolipid synthesis by increasing SPT activity and mRNA levels.

The host response to infection and inflammation is accompanied by changes in hepatic synthesis of acute-phase proteins.²³ During the acute-phase response, hepatic synthesis of several proteins, such as C-reactive protein, serum amyloid A, and HMG-CoA reductase, is increased, whereas the synthesis of several other proteins, such as albumin, transferrin, and apoE, is inhibited.^{4 23} These changes in hepatic acute-phase protein synthesis are primarily regulated at the level of gene transcription.²² The acute-phase response in rodents is also accompanied by stimulation of hepatic fatty acid and cholesterol synthesis and a marked increase in serum triglyceride and cholesterol levels.²⁴ The LPS-induced increases in hepatic sphingolipid synthesis, SPT activity, and SPT mRNA levels can also be considered a part of the acute-phase response.

Many of the metabolic changes that occur during the host response to infection or inflammation are mediated by proinflammatory cytokines, such as TNF, IL-1, and IL-6 (reviewed in Hardardottir et al² ). We previously showed that these cytokines stimulate hepatic fatty acid and cholesterol synthesis and increase VLDL production and secretion.^{25 26 27} Like LPS, these cytokines also inhibit cholesterol 7-hydroxylase in the liver and lipoprotein lipase activity in adipose tissue.^{7 28} In the present study, IL-1 administration increased both SPT activity (50% to 80%) and mRNA levels (2-fold to 3-fold) in the liver of Syrian hamsters; however, TNF had no such effect on SPT activity or mRNA levels in intact animals. Conversely, treatment of HepG2 cells, a human hepatoma cell line, with TNF, IL-1, or IL-6 increased SPT mRNA levels by 2-fold to 3-fold. Compared with TNF, IL-1 had a greater effect in HepG2 cells and also increased the secretion of sphingolipids into the medium. There are 2 potential explanations for the difference between the effects of TNF and IL-1 on sphingolipid metabolism in Syrian hamsters and HepG2 cells. First, it is possible that the results obtained are simply due to differences in species responses (ie, TNF stimulates sphingolipid metabolism in humans but not hamsters). Moreover, HepG2 cells are derived from a liver carcinoma cell line and thus may respond differently to various treatments than human or rodent hepatocytes. Second, these differences could be due to a dose or timing phenomenon (ie, at higher doses or different times, TNF might be effective in vivo). In either case, these studies demonstrate that cytokines, which mediate the acute-phase response, are capable of regulating hepatic sphingolipid metabolism.

It is now widely recognized that many of the actions of cytokines are mediated by the hydrolysis of sphingomyelin to ceramide by the activation of sphingomyelinases (reviewed by Chatterjee²⁹ ). Ceramide is an important signal transduction molecule that acts as a second messenger in a variety of biological processes, such as regulation of cell proliferation and differentiation, apoptosis, and immune and inflammatory responses.^{30 31} Ceramide is also a precursor for other sphingolipid mediators, such as sphingosine-1-phosphate.³² It is therefore possible that the LPS-induced increase in hepatic sphingolipid synthesis provides additional substrate (ie, sphingomyelin and ceramide) for these cytokine signaling pathways. It is also possible that the increase in ceramide synthesis in liver may be involved in the hepatotoxic effects of LPS.

The primary function of the acute-phase response is to protect the organism from further injury and help in the repair response.²² However, if this response to infection or inflammatory stimuli is protracted or sustained, it may have deleterious consequences.³³ Several epidemiological studies have suggested a link between chronic infections or the acute-phase response and atherosclerosis. There is an increased incidence of coronary heart disease in patients with Helicobacter pylori or Chlamydia pneumoniae infections, chronic dental infections, chronic bronchitis, and rheumatoid arthritis.^{34 35 36 37 38} C-reactive protein levels, a marker for the acute-phase response, are also elevated in patients with coronary heart disease, stroke, and unstable angina.³⁹ Thus, it is possible that some of the changes produced during the acute-phase response may have effects that could promote atherogenesis.

We and others have shown that LPS-induced stimulation of hepatic fatty acid and cholesterol synthesis leads to changes in the composition of lipoproteins, resulting in cholesterol-rich and triglyceride-rich LDL particles that may be proatherogenic.^{4 40} Sphingolipids, such as sphingomyelin, ceramide, and glucosylceramide, are integral components of lipoproteins.^{8 41 42} In this study, we demonstrated that the VLDL, IDL, and LDL fractions contain markedly higher levels of ceramide, glucosylceramide, and sphingomyelin, whereas HDL contains higher amounts of ceramide and glucosylceramide. Recent studies by Merrill et al⁸ have shown that de novo sphingolipid synthesis is not essential for lipoprotein secretion and that dietary changes that alter the rate of VLDL secretion do not alter the rate of hepatic sphingolipid synthesis. However, an increase in hepatic sphingolipid synthesis during the host response to LPS, in conjunction with an LPS-induced increase in cholesterol and triglyceride synthesis, could alter the structure or functions of lipoproteins.

An increase in these sphingolipid levels in lipoproteins could have a number of consequences that may increase the atherogenicity of lipoprotein particles. For example, it was recently shown that increased ceramide levels in LDL facilitate LDL aggregation, which, in turn, enhances their uptake by macrophages, leading to foam cell formation.⁴³ Moreover, LDL isolated from atherosclerotic lesions is either aggregated or has an increased tendency to aggregate and is enriched 10-fold to 50-fold in ceramides compared with plasma LDL.⁴⁴ An increase in sphingomyelin in lipoproteins could also exert proatherogenic effects. Sphingomyelin is the substrate for the formation of ceramide by sphingomyelinases in the arterial wall and macrophages.⁴³ Sphingomyelin inhibits the activity of lecithin-cholesterol acyltransferase,^{45 46} which could decrease the reverse–cholesterol transport pathway, thereby increasing the risk of atherogenesis. Sphingomyelin also slows the clearance of triglyceride-rich lipoproteins,⁴⁷ which could result in an accumulation of VLDL and chylomicron remnant particles that are atherogenic. Several earlier studies have shown that sphingomyelin accumulates in parallel with cholesterol within the arterial intima during experimental atherogenesis.^{48 49} More recently, it was reported that there is marked accumulation of glucosylceramide and lactosylceramide in human atherosclerotic plaques.^{50 51} The activity of SPT, the rate-limiting enzyme in sphingolipid synthesis, is also increased in rabbit aorta during experimental atherogenesis.⁵² Taken together, these findings support the concept that enhanced sphingolipid synthesis leading to the enrichment of lipoproteins with ceramide, glucosylceramide, and sphingomyelin may be an important determinant of their atherogenic potential.

In addition to the increased ceramide levels in LDL isolated from atherosclerotic lesions^{43 44} and the increased sphingolipid levels in lipoproteins isolated from LPS-treated animals reported here, several other changes are produced during the acute-phase response that could be proatherogenic. During the acute-phase response, marked changes occur in HDL-associated enzymes that result in the loss of protective function of HDL and convert it to a proinflammatory molecule (reviewed in Berliner⁵³ ). These changes include marked decreases in HDL-associated apoA-I, paraoxonase, and platelet-activating factor (PAF)–acetylhydrolase.^{54 55 56} ApoA-I has been shown to prevent aggregation of LDL,⁵⁷ whereas paraoxonase and PAF-acetylhydrolase normally protect LDL from oxidation by biologically active lipids.^{54 55 56} However, when these enzymes are depleted during the acute-phase response, there is a reciprocal increase in serum amyloid A, ceruloplasmin, and apoJ in the acute-phase HDL, which results in an increased susceptibility of LDL to oxidation.^{53 54 55 56} We and others have shown that LPS and cytokines produce similar changes in apoA-I, serum amyloid A, and apoJ protein and mRNA levels in rodents.^{1 16 58} LPS and cytokines also decrease the protein and mRNA levels of lecithin-cholesterol acyltransfease, another HDL-associated enzyme that plays a key role in reverse cholesterol transport.⁵⁹ A decrease in reverse cholesterol transport could increase the risk of atherogenesis. Sphingomyelin also inhibits the activity of lecithin-cholesterol acyltransferase^{45 46} Thus, the host response to infection and inflammatory stimuli is accompanied by several changes that could increase the atherogenicity of lipoprotein particles.

In summary, this study demonstrated that LPS increases the activity and mRNA levels of SPT, a key regulatory enzyme in sphingolipid synthesis, in liver. Cytokines, particularly IL-1, mimic the effects of LPS on SPT activity in vivo and also directly regulate SPT mRNA levels in HepG2 cells. LPS enhances hepatic sphingolipid synthesis, and the lipoproteins isolated from LPS-treated animals are enriched in sphingomyelin, ceramide, and glucosylceramide. These changes in lipoprotein composition may alter their structure and function and enhance their atherogenic potential.

	Acknowledgments

 
This work was supported by grants from the Research Service of the Department of Veterans Affairs (C.G., K.R.F.) and the National Institutes of Health (C.G.) (DK 49448).

Received December 23, 1997; accepted February 24, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Cabana VG, Siegel JN, Sabesin SM. Effect of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989;30:39–49.[Abstract]

2. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol. 1994;5:207–215.[Medline] [Order article via Infotrieve]

3. Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doerrler W, Dinarello CA, Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res. 1992;33:1765–1776.[Abstract]

4. Feingold KR, Hardardottir I, Memon RA, Krul EJ, Moser AH, Taylor JM, Grunfeld C. The effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res. 1993;34:2147–2158.[Abstract]

5. Feingold KR, Pollock AS, Moser AH, Shigenaga JK, Grunfeld C. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res. 1995;36:1474–1482.[Abstract]

6. Memon RA, Shechter I, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin, tumor necrosis factor and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. J Lipid Res. 1997;38:1620–1629.[Abstract]

7. Feingold KR, Spady DK, Pollock AS, Moser AH, Grunfeld C. Endotoxin, TNF, and IL-1 decrease cholesterol 7-alpha-hydroxylase mRNA levels and activity. J Lipid Res. 1996;37:223–228.[Abstract]

8. Merrill AH Jr, Hannun YA, Bell RM. Sphingolipids and their metabolites in cell regulation. Adv Lipid Res. 1993;25:1–24.[Medline] [Order article via Infotrieve]

9. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996;274:1855–1859.[Abstract/Free Full Text]

10. Spiegel S, Foster D, Kolesnick R. Signal transduction through lipid second messengers. Curr Opin Cell Biol. 1996;8:159–167.[Medline] [Order article via Infotrieve]

11. Merrill AH Jr, Lingrell S, Wang E, Nikolana-Karakashian M, Valen TR, Vance DE. Sphingolipid biosynthesis de novo by rat hepatocytes in culture: ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. J Biol Chem. 1995;270:13834–13841.[Abstract/Free Full Text]

12. Messmer TD, Wang E, Stevens VL, Merrill AH Jr. Sphingolipid biosynthesis by rat liver cells: effects of serine, fatty acids, and lipoproteins. J Nutr. 1989;119:534–538.

13. Williams RD, Wang E, Merrill AH Jr. Enzymology of long-chain base synthesis by liver: characterization of serine palmitoyltransferase in rat liver microsomes. Arch Biochem Biophys. 1984;228:282–291.[Medline] [Order article via Infotrieve]

14. Nagiec MM, Lester RL, Dickson RC. Sphingolipid synthesis: identification and characterization of mammalian cDNAs encoding the Lcb2 subunit of serine palmitoyltransferase. Gene. 1996;177:237–241.[Medline] [Order article via Infotrieve]

15. Hardardottir I, Moser AH, Memon R, Grunfeld C, Feingold KR. Effects of TNF, IL-1 and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res. 1994;13:161–166.[Medline] [Order article via Infotrieve]

16. Holleran WM, Feingold KR, Mao-Qiang M, Gao WN, Lee JM, Elias PM. Regulation of epidermal sphingolipid synthesis by permeability barrier function. J Lipid Res. 1991;32:1151–1158.[Abstract]

17. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.[Medline] [Order article via Infotrieve]

18. Morrow JF, Steraman RS, Peltzman CG, Potter DA. Induction of hepatic synthesis of serum amyloid A and actin. Proc Natl Acad Sci U S A. 1981;78:4718–4722.[Abstract/Free Full Text]

19. Memon RA, Feingold KR, Moser AH, Fuller J, Grunfeld C. Regulation of fatty acid transport protein and fatty acid translocase mRNA levels by endotoxin and cytokines. Am J Physiol. 1998;274:E210–E217.[Abstract/Free Full Text]

20. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917.

21. Jiao S, Cole TG, Kitchens RT, Pfleger B, Schonfeld G. Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. Metabolism. 1990;39:155–160.[Medline] [Order article via Infotrieve]

22. Holleran WM, Mao-Kiang M, Gao WN, Menon GK, Elias PM, Feingold KR. Sphingolipids are required for mammalian epidermal barrier function: inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation. J Clin Invest. 1991;88:1338–1345.

23. Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74–80.[Medline] [Order article via Infotrieve]

24. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology. 1993;132:2246–2253.[Abstract/Free Full Text]

25. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest. 1987;80:184–190.

26. Feingold KR, Soued M, Adi S, Staprans I, Neese R, Shigenaga J, Doerrler W, Moser A, Dinarello CA, Grunfeld C. The effect of interleukin-1 on lipid metabolism in the rat: similarities and differences from tumor necrosis factor. Arterioscler Thromb. 1991;11:495–500.[Abstract/Free Full Text]

27. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology. 1995;136:2143–2149.[Abstract]

28. Feingold KR, Marshall M, Gulli R, Moser AH, Grunfeld C. The effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb. 1994;14:1866–1872.[Abstract/Free Full Text]

29. Chatterjee S. Neutral sphingomyelinase. Adv Lipid Res.. 1993;26:25–48.[Medline] [Order article via Infotrieve]

30. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem. 1994;269:3125–3128.[Free Full Text]

31. Ballou LR, Laulederkind SJF, Rosloneic EF, Raghow R. Ceramide signalling and the immune response. Biochim Biophys Acta. 1996;1301:273–287.[Medline] [Order article via Infotrieve]

32. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, Satoh K, Ozaki K, Kume S. Sphingosine-1-phosphate, a bioactive sphingolipid abundantly present in platelets, is a normal constituent of human plasma and serum. J Biochem. 1997;121:969–973.[Abstract/Free Full Text]

33. Memon RA, Feingold KR, Grunfeld C. Role of cytokines in lipid metabolism and cachexia. In: Aggarwal BB, Puri RK, eds. Human Cytokines: Their Role in Health and Disease. Cambridge, Mass: Blackwell Science; 1995:239–251.

34. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437–439.[Abstract/Free Full Text]

35. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, Toosey T, Camm AJ, Northfield TC. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect. 1995;30:121–128.[Medline] [Order article via Infotrieve]

36. Mattila KJ, Valtonen VV, Nieminen M, Huttunen JK. Dental infections and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin Infect Dis. 1995;20:588–592.[Medline] [Order article via Infotrieve]

37. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996;348:567–572.[Medline] [Order article via Infotrieve]

38. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 1995;22:1065–1067.[Medline] [Order article via Infotrieve]

39. Mendall PA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular factors: a population based cross sectional study. Br Med J. 1996;312:1061–1065.[Abstract/Free Full Text]

40. Lanza-Jacoby S, Wong SH, Tabares A, Baer D, Schneider T. Disturbances in the composition of plasma lipoproteins during gram-negative sepsis in the rat. Biochim Biophys Acta. 1992;1124:233–240.[Medline] [Order article via Infotrieve]

41. Chatterjee S, Kwiterovich PO. Glycosphingolipids of human plasma lipoproteins. Lipids. 1976;11:462–466.[Medline] [Order article via Infotrieve]

42. Chapman J. Comparative analysis of mammalian plasma lipoproteins. Methods Enzymol. 1986;128:70–143.[Medline] [Order article via Infotrieve]

43. Xu X, Tabas I. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J Biol Chem. 1991;266:24849–24858.[Abstract/Free Full Text]

44. Schissel S, Tweedie-Hardman J, Rapp JL, Graham G, Williams K, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low density lipoprotein: proposed role for arterial wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 1996;98:1455–1464.[Medline] [Order article via Infotrieve]

45. Subbaiah P, Liu M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins: inhibition of lecithin-cholesterol acyltransferase reaction. J Biol Chem. 1993;268:20156–20163.[Abstract/Free Full Text]

46. Bolin D, Jones A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem. 1996;271:19152–19158.[Abstract/Free Full Text]

47. Redgrave TG, Rakic V, Mortimer B, Mamo JCL. Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins from plasma: studies with lipid emulsions in rats. Biochim Biophys Acta. 1992;1126:65–72.[Medline] [Order article via Infotrieve]

48. Buck RC, Rossiter RJ. Lipids of normal and atherosclerotic aorta. Arch Pathol. 1951;48:224–237.

49. Steele JM, Kayden HJ. The nature of phospholipids in human serum and atheromatous vessels. Trans Assoc Am Physicians. 1955;68:249–254.[Medline] [Order article via Infotrieve]

50. Mukhin DN, Chao F, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1607–1615.[Abstract/Free Full Text]

51. Chatterjee S, Dey S, Shi WN, Thomas C, Hutchins GM. Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Glycobiology. 1997;7:57–65.[Abstract/Free Full Text]

52. Williams RD, Sgoutas DS, Zaatari GS. Enzymology of long-chain base synthesis by aorta: induction of serine-palmitoyltransferase activity in rabbit aorta during atherogenesis. J Lipid Res. 1986;27:763–770.[Abstract]

53. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms oxidation, inflammation, and genetics. Circulation. 1995;91:2488–2496.[Abstract/Free Full Text]

54. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–2767.

55. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774–782.

56. Navab M, Hama SY, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan M, Lusis AJ, Fogelman AM. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005–2019.[Medline] [Order article via Infotrieve]

57. Khoo JC, Miller E, McLoughlin P, Steinberg D. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res. 1990;31:645–652.[Abstract]

58. Hardardottir I, Sipe J, Moser AH, Fielding CJ, Feingold KR, Grunfeld C. LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochim Biophys Acta. 1997;1344:210–220.[Medline] [Order article via Infotrieve]

59. Ly H, Francone OL, Fielding CJ, Shigenaga JK, Moser AH, Grunfeld C, Feingold KR. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res. 1995;36:1254–1263.[Abstract]

This article has been cited by other articles:

				N. Bartolome, B. Arteta, M. J. Martinez, Y. Chico, and B. Ochoa Kupffer cell products and interleukin 1? directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes Innate Immunity, August 1, 2008; 14(4): 255 - 266. [Abstract] [PDF]

				J. Shen, D. K. Arnett, P. Perez-Martinez, L. D. Parnell, C.-Q. Lai, J. M. Peacock, J. E. Hixson, M. Y. Tsai, R. J. Straka, P. N. Hopkins, et al. The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN study,boxs J. Lipid Res., August 1, 2008; 49(8): 1839 - 1845. [Abstract] [Full Text] [PDF]

				W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF]

				C. Popa, F. H J van den Hoogen, T. R D J Radstake, M. G Netea, A. E Eijsbouts, M. d. Heijer, J. W M van der Meer, P. L C M van Riel, A. F H Stalenhoef, and P. Barrera Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis Ann Rheum Dis, November 1, 2007; 66(11): 1503 - 1507. [Abstract] [Full Text] [PDF]

				C. Popa, M. G. Netea, P. L. C. M. van Riel, J. W. M. van der Meer, and A. F. H. Stalenhoef The role of TNF-{alpha} in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk J. Lipid Res., April 1, 2007; 48(4): 751 - 762. [Abstract] [Full Text] [PDF]

				D. K. Singh and P. V. Subbaiah Modulation of the activity and arachidonic acid selectivity of group X secretory phospholipase A2 by sphingolipids J. Lipid Res., March 1, 2007; 48(3): 683 - 692. [Abstract] [Full Text] [PDF]

				Q. He, H. Suzuki, N. Sharma, and R. P. Sharma Ceramide Synthase Inhibition by Fumonisin B1 Treatment Activates Sphingolipid-Metabolizing Systems in Mouse Liver Toxicol. Sci., December 1, 2006; 94(2): 388 - 397. [Abstract] [Full Text] [PDF]

				V E MacRae, T Burdon, S F Ahmed, and C Farquharson Ceramide inhibition of chondrocyte proliferation and bone growth is IGF-I independent. J. Endocrinol., November 1, 2006; 191(2): 369 - 377. [Abstract] [Full Text] [PDF]

				P. Aspichueta, B. Perez-Agote, S. Perez, B. Ochoa, and O. Fresnedo Impaired response of VLDL lipid and apoB secretion to endotoxin in the fasted rat liver Innate Immunity, June 1, 2006; 12(3): 181 - 191. [Abstract] [PDF]

				V. E. MacRae, C. Farquharson, and S. F. Ahmed The pathophysiology of the growth plate in juvenile idiopathic arthritis Rheumatology, January 1, 2006; 45(1): 11 - 19. [Abstract] [Full Text] [PDF]

				K. Strle, S. R. Broussard, R. H. McCusker, W.-H. Shen, R. W. Johnson, G. G. Freund, R. Dantzer, and K. W. Kelley Proinflammatory Cytokine Impairment of Insulin-Like Growth Factor I-Induced Protein Synthesis in Skeletal Muscle Myoblasts Requires Ceramide Endocrinology, October 1, 2004; 145(10): 4592 - 4602. [Abstract] [Full Text] [PDF]

				W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF]

				S.-y. Morita, M. Kawabe, A. Sakurai, K. Okuhira, A. Vertut-Doi, M. Nakano, and T. Handa Ceramide in Lipid Particles Enhances Heparan Sulfate Proteoglycan and Low Density Lipoprotein Receptor-related Protein-mediated Uptake by Macrophages J. Biol. Chem., June 4, 2004; 279(23): 24355 - 24361. [Abstract] [Full Text] [PDF]

				S. Malagarie-Cazenave, B. Segui, S. Leveque, V. Garcia, S. Carpentier, M.-F. Altie, A. Brouchet, V. Gouaze, N. Andrieu-Abadie, Y. Barreira, et al. Role of FAN in Tumor Necrosis Factor-{alpha} and Lipopolysaccharide-induced Interleukin-6 Secretion and Lethality in D-Galactosamine-sensitized Mice J. Biol. Chem., April 30, 2004; 279(18): 18648 - 18655. [Abstract] [Full Text] [PDF]

				B. Boyanovsky, A. Karakashian, K. King, N. Giltiay, and M. Nikolova-Karakashian Uptake and Metabolism of Low Density Lipoproteins with Elevated Ceramide Content by Human Microvascular Endothelial Cells: IMPLICATIONS FOR THE REGULATION OF APOPTOSIS J. Biol. Chem., July 11, 2003; 278(29): 26992 - 26999. [Abstract] [Full Text] [PDF]

				J. M. Carton, D. J. Uhlinger, A. D. Batheja, C. Derian, G. Ho, D. Argenteri, and M. R. D'Andrea Enhanced Serine Palmitoyltransferase Expression in Proliferating Fibroblasts, Transformed Cell Lines, and Human Tumors J. Histochem. Cytochem., June 1, 2003; 51(6): 715 - 726. [Abstract] [Full Text] [PDF]

				J.-Y. Yoo and S. Desiderio Innate and acquired immunity intersect in a global view of the acute-phase response PNAS, February 4, 2003; 100(3): 1157 - 1162. [Abstract] [Full Text] [PDF]

				Y. Uchida, S. Murata, M. Schmuth, M. J. Behne, J. D. Lee, S. Ichikawa, P. M. Elias, Y. Hirabayashi, and W. M. Holleran Glucosylceramide synthesis and synthase expression protect against ceramide-induced stress J. Lipid Res., August 1, 2002; 43(8): 1293 - 1302. [Abstract] [Full Text] [PDF]

				A. H. Merrill Jr. De Novo Sphingolipid Biosynthesis: A Necessary, but Dangerous, Pathway J. Biol. Chem., July 12, 2002; 277(29): 25843 - 25846. [Full Text] [PDF]

				R. A. Memon, W. M. Holleran, Y. Uchida, A. H. Moser, C. Grunfeld, and K. R. Feingold Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin J. Lipid Res., March 1, 2001; 42(3): 452 - 459. [Abstract] [Full Text]

				S. Barlage, D. Fröhlich, A. Böttcher, M. Jauhiainen, H. P. Müller, F. Noetzel, G. Rothe, C. Schütt, R. P. Linke, K. J. Lackner, et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response J. Lipid Res., February 1, 2001; 42(2): 281 - 290. [Abstract] [Full Text]

				R. A. Memon, I. Staprans, M. Noor, W. M. Holleran, Y. Uchida, A. H. Moser, K. R. Feingold, and C. Grunfeld Infection and Inflammation Induce LDL Oxidation In Vivo Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1536 - 1542. [Abstract] [Full Text] [PDF]

				R. A. Memon, W. M. Holleran, Y. Uchida, A. H. Moser, S. Ichikawa, Y. Hirabayashi, C. Grunfeld, and K. R. Feingold Regulation of Glycosphingolipid Metabolism in Liver during the Acute Phase Response J. Biol. Chem., July 9, 1999; 274(28): 19707 - 19713. [Abstract] [Full Text] [PDF]

				R. A. Memon, J. Fuller, A. H. Moser, K. R. Feingold, and C. Grunfeld In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response Am J Physiol Regulatory Integrative Comp Physiol, July 1, 1999; 277(1): R94 - R103. [Abstract] [Full Text] [PDF]

				B. J. Van Lenten, A. C. Wagner, M. Navab, and A. M. Fogelman Oxidized Phospholipids Induce Changes in Hepatic Paraoxonase and ApoJ but Not Monocyte Chemoattractant Protein-1 via Interleukin-6 J. Biol. Chem., January 12, 2001; 276(3): 1923 - 1929. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Memon, R. A. Articles by Feingold, K. R. Search for Related Content PubMed PubMed Citation Articles by Memon, R. A. Articles by Feingold, K. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH